Evidence map›Paper›PMID 18439349›Full record

ArticleEmerging infectious diseases2008

Scale-up of multidrug-resistant tuberculosis laboratory services, Peru.

Sonya S Shin, Martin Yagui, Luis Ascencios, Gloria Yale, Carmen Suarez, Neyda Quispe, Cesar Bonilla, Joaquin Blaya, Allison Taylor, Carmen Contreras and 1 more

Abstract read
In one paragraph

Article in Emerging infectious diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Electronic laboratory system reduces errors in National Tuberculosis Program: a cluster randomized controlled trial.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2010
    Trial
  2. Trial
  3. Article
  4. The fourth national anti-tuberculosis drug resistance survey in Peru.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2020
    Article
  5. Article
  6. Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2017
    Article
  7. Article
  8. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2017
    Review
  9. Article
  10. Article
  11. Article
  12. Salvage therapy for multidrug-resistant tuberculosis.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2014
    Article
  13. Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in Peru.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2013
    Article
  14. Review
  15. Impact of rapid drug susceptibility testing for tuberculosis: program experience in Lima, Peru.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2012
    Article
  16. Article
  17. Article
  18. The Innovative Socio-economic Interventions Against Tuberculosis (ISIAT) project: an operational assessment.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2011
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sonya S ShinDivision of Social Medicine and Health Inequalities, Brigham and Women's Hospital, Boston, Massachusetts 02120, USA. sshin@partners.org
Martin Yagui
Luis Ascencios
Gloria Yale
Carmen Suarez
Neyda Quispe
Cesar Bonilla
Joaquin Blaya
Allison Taylor
Carmen Contreras
Peter Cegielski

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past 10 years, the Peruvian National Tuberculosis (TB) Program, the National Reference Laboratory (NRL), Socios en Salud, and US partners have worked to strengthen the national TB laboratory network to support treatment of multidrug-resistant TB. We review key lessons of this experience. The preparation phase involved establishing criteria for drug susceptibility testing (DST), selecting appropriate DST methods, projecting the quantity of DST and culture to ensure adequate supplies, creating biosafe laboratory facilities for DST, training laboratory personnel on methods, and validating DST methods at the NRL. Implementation involved training providers on DST indications, validating conventional and rapid first-line DST methods at district laboratories, and eliminating additional delays in specimen transport and result reporting. Monitoring included ongoing quality control and quality assurance procedures. Hurdles included logistics, coordinating with policy, competing interests, changing personnel, communications, and evaluation. Operational research guided laboratory scale-up and identified barriers to effective capacity building.

Indexed as

LaboratoriesProgram EvaluationAntitubercular AgentsCulture MediaHumansMicrobial Sensitivity TestsMicrobiological TechniquesMycobacterium tuberculosisPeruProgram DevelopmentQuality Assurance, Health CareTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryAntitubercular AgentsCulture Media

Identifiers

PMID18439349
PMCPMC2600242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.